Nurix Therapeutics, Inc.
NASDAQTotal Valuation
Nurix Therapeutics, Inc. carries a market capitalization of 2.03B, placing it among publicly traded companies globally. Its enterprise value stands at 1.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.03B |
| Enterprise Value | 1.39B |
Share Statistics
Nurix Therapeutics, Inc. currently has 103.70M shares outstanding.
| Shares Outstanding | 103.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 48.35, and the price-to-book ratio stands at -1.51.
| PE Ratio | N/A |
| PS Ratio | 48.35 |
| PB Ratio | -1.51 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | -6.28 |
| P/OCF Ratio | -6.05 |
Enterprise Valuation
| EV / Sales | 37.87 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Nurix Therapeutics, Inc. maintains a current ratio of 6.34, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.34 |
| Quick Ratio | 6.16 |
| Debt / Equity | 14.44 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -60.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -271,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Nurix Therapeutics, Inc.'s stock has gained approximately 108.71111% over the past 52 weeks. The 50-day moving average sits at 19.02, while the 200-day moving average is 16.47.
| Beta (5Y) | N/A |
| 52-Week Price Change | 108.71111% |
| 50-Day Moving Average | 19.02 |
| 200-Day Moving Average | 16.47 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nurix Therapeutics, Inc. generated 36.77M in revenue and converted that into -341.35M in net income, yielding earnings per share of -3.41. EBITDA reached -343.92M, while operating income came in at -361.18M.
| Revenue | 36.77M |
| Gross Profit | N/A |
| Operating Income | -361.18M |
| Pretax Income | -341.62M |
| Net Income | -341.35M |
| EBITDA | -343.92M |
| EBIT | -361.18M |
| Earnings Per Share (EPS) | -3.41 |
Balance Sheet
Nurix Therapeutics, Inc. holds 443.53M in cash and equivalents against 58.14M in total debt, resulting in a net debt position of -67.68M. Total book value stands at -1.18B, with working capital of 384.46M providing operational flexibility.
| Cash & Cash Equivalents | 443.53M |
| Total Debt | 58.14M |
| Net Debt | -67.68M |
| Equity (Book Value) | -1.18B |
| Book Value Per Share | -11.79 |
| Working Capital | 384.46M |
Cash Flow
Nurix Therapeutics, Inc. produced -293.70M in operating cash flow over the past twelve months. After subtracting -10.82M in capital expenditures, free cash flow totaled -304.53M - equivalent to -3.04 per share.
| Operating Cash Flow | -293.70M |
| Capital Expenditures | -10.82M |
| Free Cash Flow | -304.53M |
| FCF Per Share | -3.04 |
Margins
Nurix Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -982.37 and net profit margin of -928.44 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -982.37 |
| Pretax Margin | -929.18 |
| Profit Margin | -928.44 |
| EBITDA Margin | -935.43 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.47 |
| FCF Yield | -15.91 |
Scores
Nurix Therapeutics, Inc. posts an Altman Z-Score of 3.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.65 |